Literature DB >> 19050321

2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.

Sumie Kato1, Anil Sadarangani, Soledad Lange, Ana M Delpiano, Macarena Vargas, Jorge Brañes, Jorge Carvajal, Stanley Lipkowitz, Gareth I Owen, Mauricio A Cuello.   

Abstract

OBJECTIVE: The estrogen metabolite 2-methoxyestradiol has shown antitumorigenic action in some epithelial tumors. In the present work we investigate its effects in ovarian cancer used alone or in combination with other apoptotic-inducing reagents such as tumor necrosis factor-related apoptosis-inducing ligand.
METHODS: To assess the effect of 2-methoxyestradiol, dose response and time courses in ovarian cancer and normal cells were conducted. Apoptosis was confirmed through DNA laddering, by flow cytometry, and Western blotting of proteins involved in the apoptotic cascade.
RESULTS: 2-Methoxyestradiol induced apoptosis in ovarian cancer cells but not in normal counterparts. 2-Methoxyestradiol activates both the intrinsic and extrinsic apoptotic pathways. 2-Methoxyestradiol-mediated apoptosis involves reactive oxygen species generation and caspase-dependent and caspase-independent mechanisms. We also demonstrate that 2-methoxyestradiol selectively induces an additive/synergistic apoptotic response in ovarian cancer cells when used in combination with tumor necrosis factor-related apoptosis-inducing ligand.
CONCLUSIONS: 2-Methoxyestradiol, alone or in combination with tumor necrosis factor-related apoptosis-inducing ligand, should be considered as a potential treatment for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050321      PMCID: PMC9019574          DOI: 10.1177/1933719108324171

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  53 in total

Review 1.  Diagnosis and management of epithelial ovarian cancer.

Authors:  Snehal Bhoola; William J Hoskins
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

2.  Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells.

Authors:  Shizhong Bu; Andree Blaukat; Xin Fu; Nils Erik Heldin; Maréne Landström
Journal:  FEBS Lett       Date:  2002-11-06       Impact factor: 4.124

3.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

Authors:  M Cuello; S A Ettenberg; A S Clark; M M Keane; R H Posner; M M Nau; P A Dennis; S Lipkowitz
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

4.  Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor.

Authors:  S Ray; O Bucur; A Almasan
Journal:  Apoptosis       Date:  2005-12       Impact factor: 4.677

5.  Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

Authors:  M Cuello; S A Ettenberg; M M Nau; S Lipkowitz
Journal:  Gynecol Oncol       Date:  2001-06       Impact factor: 5.482

6.  TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.

Authors:  Anil Sadarangani; Sumie Kato; Natalia Espinoza; Soledad Lange; Carmen Llados; Marisol Espinosa; Manuel Villalón; Stanley Lipkowitz; Mauricio Cuello; Gareth I Owen
Journal:  Apoptosis       Date:  2007-01       Impact factor: 4.677

7.  Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice.

Authors:  Juan Shi; Dexian Zheng; Yanxin Liu; Mai Har Sham; Paul Tam; Farzin Farzaneh; Ruian Xu
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

9.  N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.

Authors:  M Cuello; A O Coats; I Darko; S A Ettenberg; G J Gardner; M M Nau; J R Liu; M J Birrer; S Lipkowitz
Journal:  Cell Death Differ       Date:  2004-05       Impact factor: 15.828

Review 10.  Current management strategies for ovarian cancer.

Authors:  Giovanni D Aletti; Mary M Gallenberg; William A Cliby; Aminah Jatoi; Lynn C Hartmann
Journal:  Mayo Clin Proc       Date:  2007-06       Impact factor: 7.616

View more
  8 in total

Review 1.  2-methoxyestradiol and disorders of female reproductive tissues.

Authors:  Mauricio P Pinto; Rodolfo A Medina; Gareth I Owen
Journal:  Horm Cancer       Date:  2014-04-25       Impact factor: 3.869

2.  Evaluation of 2-methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma.

Authors:  Igor Hrgovic; Johannes Kleemann; Monika Doll; Carmen Loquai; Florian Weid; Frank Louwen; Nadja Zoeller; Stefan Kippenberger; Roland Kaufmann; Markus Meissner
Journal:  Mol Clin Oncol       Date:  2021-05-23

3.  Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells.

Authors:  Hui-Hui Li; Ying-Jie Zhao; Yan Li; Cai-Feng Dai; Sheikh O Jobe; Xing-Sheng Yang; Xing-Fu Li; Manish S Patankar; Ronald R Magness; Jing Zheng
Journal:  Reprod Sci       Date:  2013-06-11       Impact factor: 3.060

4.  The in vitro effects of a novel estradiol analog on cell proliferation and morphology in human epithelial cervical carcinoma.

Authors:  Laura Susan Boyd; Devrim Gozuacik; Anna Margaretha Joubert
Journal:  Cell Mol Biol Lett       Date:  2018-03-20       Impact factor: 5.787

5.  Effect of Interaction between 17β-Estradiol, 2-Methoxyestradiol and 16α-Hydroxyestrone with Chromium (VI) on Ovary Cancer Line SKOV-3: Preliminary Study.

Authors:  Ewa Sawicka; Jolanta Saczko; Joanna Roik; Julita Kulbacka; Agnieszka Piwowar
Journal:  Molecules       Date:  2020-11-09       Impact factor: 4.411

6.  Cell Fate following Irradiation of MDA-MB-231 and MCF-7 Breast Cancer Cells Pre-Exposed to the Tetrahydroisoquinoline Sulfamate Microtubule Disruptor STX3451.

Authors:  Scott D Hargrave; Anna M Joubert; Barry V L Potter; Wolfgang Dohle; Sumari Marais; Anne E Mercier
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

7.  Molecular crosstalk between apoptosis and autophagy induced by a novel 2-methoxyestradiol analogue in cervical adenocarcinoma cells.

Authors:  Anne E Theron; Elsie M Nolte; Laurence Lafanechère; Annie M Joubert
Journal:  Cancer Cell Int       Date:  2013-08-27       Impact factor: 5.722

8.  Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin.

Authors:  Lara Gibellini; Marcello Pinti; Milena Nasi; Sara De Biasi; Erika Roat; Linda Bertoncelli; Andrea Cossarizza
Journal:  Cancers (Basel)       Date:  2010-06-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.